Compare DRCT & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | PRFX |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.6M |
| IPO Year | 2021 | 2020 |
| Metric | DRCT | PRFX |
|---|---|---|
| Price | $2.98 | $1.64 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 3.9M |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,694,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.58 |
| 52 Week High | $7.21 | $5.39 |
| Indicator | DRCT | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 48.92 |
| Support Level | $2.73 | $1.00 |
| Resistance Level | $2.98 | $2.89 |
| Average True Range (ATR) | 0.22 | 0.59 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 33.32 | 9.11 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.